Mycophenolate
- 1 lab in 1 country
- 1 finding against
- 2 trials, none about aging
- Funders: American Thoracic Society and others
- Humans1
Outcomes
1Mortality
no changein humans1
1 study
Mortality
no changein humans1
Mycophenolate has no effect on mortality in humans.
“Immunosuppressant exposure was not associated with differential survival in patients with LTL ≥10th percentile.”
Humansin patients with LTL >=10th percentile2-year
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
The European respiratory journal
Associations
1Mortality
upin humans1HR 4.97
1 study
Mortality
upin humans1HR 4.97
Mycophenolate raises the risk of mortality in humans (HR 4.97, 95% CI 2.26-10.92, p<0.001).
“fHP and uILD patients with LTL <10th percentile experienced reduced survival when exposed to either mycophenolate or azathioprine in the discovery cohort (mortality hazard ratio (HR) 4.97, 95% CI 2.26-10.92; p<0.001)”
Humansin fHP and uILD patients with LTL <10th percentile (discovery cohort)2-yearn = 613
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
The European respiratory journal
Trial sponsors
Novartis Pharmaceuticals Corporation
Company1 trialPhase 4126 people
Company1 trialPhase 2/3526 people
Latest
3 papers in 12 monthsScience Advances
VCAM-1-targeting peptide assemblies protect vascular endothelium and prolong cardiac xenograft survival
Experiments in pigsInterventions
bioRxiv
Coordinated circulating and tissue-based T cell responses precede xenograft rejection
Preprint: case reportGraft rejection
Frontiers in Aging
Sirolimus use in allogeneic hematopoietic cell transplant recipients: assessing its senotherapeutic role in a high risk population
Cohort study in peopleRapamycin
Hematology American Society of Hematology Education Program
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome
ReviewInterventions
The European Respiratory Journal
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
Cohort study of 613 peopleTelomere length